Skip to main content

DarioHealth Corp.

corporate_fare Company Profile

DarioHealth Corp.

DRIO·NASDAQ·Life Sciences·CIK 0001533998

Dario is a vertically integrated health intelligence platform focused on powering behavior changes for better health. The company manages the entire chronic care management process, including connected FDA-cleared hardware devices that generate continuous physiological data, AI built on this proprietary data, and a behavior change and coaching layer supported by over 100 peer-reviewed clinical studies. Dario aims to transform healthcare through a comprehensive and engaging whole-person health platform. The company's approach emphasizes engagement, believing that many existing digital health solutions fail due to a lack of relevance, personalization, consumerization, and longitudinal data. Dario, along with its acquired companies, initially commercialized its digital behavioral health products in the direct-to-consumer (D2C) marketplace, which it continues to use for innovation. D2C consumers, who pay out-of-pocket, demand engaging user experiences that deliver strong clinical health outcomes. Dario prioritizes engagement to drive sustained behavior change and measurable health outcomes. The company believes its D2C origins and focus lead to better user experiences, longer engagement, stronger clinical outcomes, and affordable prices, resulting in high return on investment. Dario's whole-person health model includes five elements, starting with Physical Health, which addresses the prevention and treatment of physical ailments, primarily cardiometabolic and musculoskeletal conditions.

DarioHealth Corp. (NASDAQ:DRIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for DRIO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • DarioHealth Projected to Post $3.24/Share Loss, Revenue Down 33% Ahead of Earnings
  • DarioHealth Sees Strong Demand for Oral GLP-1 Solution
  • Shareholders Approve Significant Dilution from Past Financings and Future Equity Plan

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$22.36M
Net Income
-$41.71M
Diluted EPS
$10.12
Op. Cash Flow
-$25.94M
Free Cash Flow
-$26.08M
Gross Profit
$12.66M
Operating Income
-$36.66M
Cash & Equivalents
$21.8M
Total Debt
$30.75M
Debt / Equity
0.45×
Net Margin
-186.6%
Shares Outstanding
6.91M sh
Source: 10-K · filed 2026-03-19 · accession 0001104659-26-031621
$1.32
52-week range · as of 2026-11-12 $1.32 – $14.77
Market cap
$14.9M
Volume
28.2K (0.4× avg)
3-mo avg 74.7K
Live data · 2026-11-22 03:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DRIO - Filings & News (Page 2)

DRIO
Mar 06, 2026, 7:34 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.21
Real-time Price: $1.32 info
Change: -$7.89 (-86%) info
Market Cap: $14.899M info
DRIO
Mar 03, 2026, 8:02 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $10.75
Real-time Price: $1.32 info
Change: -$9.43 (-88%) info
Market Cap: $14.899M info
DRIO
Jan 29, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.30
Real-time Price: $1.32 info
Change: -$8.98 (-87%) info
Market Cap: $14.899M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets